Could Molnupiravir Have an Ameliorative Effect in Pets with COVID-19?

Abstract

Since the last months of 2019, SARS-CoV-2, commonly referred to as COVID-19, has impacted the global economy and health care industries. Previous studies on SARS-CoV-2 have shown that it can also affect household pets. Coronaviruses have long been associated with pets, and prophylaxis is provided through vaccination programs. Today, although the levels of those requiring intensive care and death rates are decreasing through the extensive vaccination program initiated for humans, there is still no effective treatment for humans or pets. SARS-CoV-2 can spread and infect animals through similar mechanisms to that of humans. Like other types of coronavirus, Feline Infectious Peritonitis (FIP)-like multi-organ failure can develop in pets with COVID-19. Until now, supportive treatment has been performed to prevent severe cases and improve the quality of life. Molnupiravir, approved for emergency use by the FDA, is a prodrug of ribonucleoside analog with a low incidence of adverse side effects. Studies have shown that Molnupiravir has a preservative effect by preventing SARS-CoV-2 viral replication. Therefore we propose that Molnupiravir may also be used as a protective agent for pets and thus prevent multiple organ failures.